Global CDMO footprint Delpharm operates 18 industrial sites across France, Italy, Canada, the Netherlands and Poland with capabilities spanning tablets, capsules, injectables, prefilled syringes and more, indicating strong capacity for scale plus multi-form manufacturing partnerships.

Vaccine and biologics momentum Past collaborations with BioNTech for COVID vaccines and Pfizer for fill-finish indicate readiness to handle sterile injectable programs and high-demand vaccines, presenting opportunities for new vaccine, mRNA, or biologic finish-and-pack collaborations.

Scale and expansion Recent investments including facility upgrades in Canada and Europe, plus a $60M financing event, signal ongoing capacity expansion and modernization, creating openings for long-term contracts and diversified product lines.

Clinical development support Delpharm offers full development services and phase 1–3 clinical batch production, enabling partnerships across drug development stages from early formulation to commercialization, appealing to mid-size and specialty biopharma seeking integrated CDMO support.

Strategic partnerships Existing collaborations with global players and a wide portfolio of dosage forms position Delpharm as a versatile partner for contract manufacturing, fill-finish, and development services, suitable for companies seeking nearshore or European-based manufacturing options.